Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| MRNA | Moderna, Inc. | 1.11% | 62.18 | 0.0% | $1999.69m | |
| REGN | Regeneron Pharmaceuticals, Inc. | -2.18% | 599.47 | 2.5% | $1212.04m | |
| GILD | Gilead Sciences, Inc. | -3.43% | 75.16 | 1.0% | $972.03m | |
| NVAX | Novavax, Inc. | 14.73% | 52.82 | 102.0% | $711.68m | |
| AMGN | Amgen, Inc. | -1.22% | 226.91 | 1.3% | $619.06m | |
| VRTX | Vertex Pharmaceuticals, Inc. | -0.46% | 286.64 | 1.9% | $592.02m | |
| BIIB | Biogen, Inc. | -1.84% | 301.45 | 1.6% | $385.60m | |
| ILMN | Illumina, Inc. | 0.65% | 365.41 | 3.5% | $384.25m | |
| SRNE | Sorrento Therapeutics, Inc. | -0.99% | 5.00 | 1.8% | $320.03m | |
| ALXN | Alexion Pharmaceuticals, Inc. | -0.82% | 118.92 | 2.0% | $296.17m | |
| SGEN | Seattle Genetics, Inc. | 1.15% | 159.02 | 6.1% | $258.80m | |
| A | Agilent Technologies, Inc. | 2.01% | 89.91 | 1.6% | $212.68m | |
| BMRN | BioMarin Pharmaceutical, Inc. | 0.79% | 107.39 | 4.3% | $185.56m | |
| MGNX | MacroGenics, Inc. | 9.67% | 21.10 | 6.2% | $174.18m | |
| INCY | Incyte Corp. | -0.16% | 101.75 | 2.5% | $166.58m |
Company Profile
Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. Its products include Tavalisse, Fostamatinib and R835. The company was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.